FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327728823> ?p ?o ?g. }

• W4327728823 endingPage "930" @default.
• W4327728823 startingPage "930" @default.
• W4327728823 abstract "(1) Background: TNF antagonists have been used to treat autoimmune diseases (AD). However, during the chronic phase of toxoplasmosis, TNF-α and TNFR play a significant role in maintaining disease resistance and latency. Several studies have demonstrated the risk of latent infections' reactivation in patients infected with toxoplasmosis. Our objective was to verify whether patients with autoimmune rheumatic diseases, who use TNF antagonists and/or synthetic drugs and had previous contact with Toxoplasma gondii (IgG+), present any indication of an increased risk of toxoplasmosis reactivation. (2) Methods: Blood samples were collected, and peripheral blood mononuclear cells (PBMCs) were evaluated after stimulation with antigens of Toxoplasma gondii, with anti-CD3/anti-CD28 or without stimulus, at 48 and 96 h. CD69+, CD28+, and PD-1 stains were evaluated, in addition to intracellular expression of IFN-γ, IL-17, and IL-10 by CD4+ and the presence of regulatory CD4+ T cells by labeling CD25+, FOXP3, and LAP. The cytokines IL-2, IL-4, IL-6, IL-10, IFN-γ, TNF-α, and IL-17 were measured in the culture supernatant after 96 h. Serology for IgG and IgG1 was evaluated. (3) Results: There were no differences in the levels of IgG and IgG1 between the groups, but the IgG1 avidity was reduced in the immunobiological group compared to the control group. All groups exhibited a significant correlation between IgG and IgG1 positivity. CD4+ T lymphocytes expressing PD-1 were increased in individuals suffering from autoimmune rheumatic diseases and using disease-modifying antirheumatic drugs. In addition, treatment with TNF blockers did not seem to influence the populations of regulatory T cells and did not interfere with the expression of the cytokines IFN-γ, IL-17, and IL-10 by CD4+ cells or the production of cytokines by PBMCs from patients with AD. (4) Conclusions: This study presents evidence that the use of TNF-α blockers did not promote an immunological imbalance to the extent of impairing the anti-Toxoplasma gondii immune response and predisposing to toxoplasmosis reactivation." @default.
• W4327728823 created "2023-03-18" @default.
• W4327728823 creator A5027455398 @default.
• W4327728823 creator A5043391459 @default.
• W4327728823 creator A5054519106 @default.
• W4327728823 creator A5054849058 @default.
• W4327728823 creator A5063815140 @default.
• W4327728823 creator A5074136202 @default.
• W4327728823 creator A5077477606 @default.
• W4327728823 creator A5084736320 @default.
• W4327728823 creator A5087126798 @default.
• W4327728823 creator A5089705166 @default.
• W4327728823 date "2023-03-17" @default.
• W4327728823 modified "2023-10-16" @default.
• W4327728823 title "Evaluation of Specific Cellular and Humoral Immune Response to Toxoplasma gondii in Patients with Autoimmune Rheumatic Diseases Immunomodulated Due to the Use of TNF Blockers" @default.
• W4327728823 cites W1489480103 @default.
• W4327728823 cites W1545910465 @default.
• W4327728823 cites W1553735692 @default.
• W4327728823 cites W1575860126 @default.
• W4327728823 cites W1662827845 @default.
• W4327728823 cites W1678438229 @default.
• W4327728823 cites W1695430850 @default.
• W4327728823 cites W1761300068 @default.
• W4327728823 cites W1840098159 @default.
• W4327728823 cites W1949902343 @default.
• W4327728823 cites W1968072341 @default.
• W4327728823 cites W1980564318 @default.
• W4327728823 cites W1992240223 @default.
• W4327728823 cites W2010708956 @default.
• W4327728823 cites W2014852139 @default.
• W4327728823 cites W2029576043 @default.
• W4327728823 cites W2029993898 @default.
• W4327728823 cites W2036543794 @default.
• W4327728823 cites W2038535814 @default.
• W4327728823 cites W2052954033 @default.
• W4327728823 cites W2066094037 @default.
• W4327728823 cites W2072313640 @default.
• W4327728823 cites W2081360252 @default.
• W4327728823 cites W2084594144 @default.
• W4327728823 cites W2085947993 @default.
• W4327728823 cites W2096922032 @default.
• W4327728823 cites W2097855813 @default.
• W4327728823 cites W2107556275 @default.
• W4327728823 cites W2114872119 @default.
• W4327728823 cites W2120249273 @default.
• W4327728823 cites W2128635872 @default.
• W4327728823 cites W2133709930 @default.
• W4327728823 cites W2134612472 @default.
• W4327728823 cites W2142273705 @default.
• W4327728823 cites W2155464214 @default.
• W4327728823 cites W2255228949 @default.
• W4327728823 cites W2279821980 @default.
• W4327728823 cites W2304614250 @default.
• W4327728823 cites W2315290629 @default.
• W4327728823 cites W2404674172 @default.
• W4327728823 cites W2546273436 @default.
• W4327728823 cites W2587720487 @default.
• W4327728823 cites W2601099967 @default.
• W4327728823 cites W2744399107 @default.
• W4327728823 cites W2793075238 @default.
• W4327728823 cites W2794524131 @default.
• W4327728823 cites W2807073140 @default.
• W4327728823 cites W2807455706 @default.
• W4327728823 cites W2901020382 @default.
• W4327728823 cites W2945327237 @default.
• W4327728823 cites W3036726363 @default.
• W4327728823 cites W3171954900 @default.
• W4327728823 cites W4286513981 @default.
• W4327728823 cites W4293247451 @default.
• W4327728823 cites W4296400934 @default.
• W4327728823 cites W4319053946 @default.
• W4327728823 doi "https://doi.org/10.3390/biomedicines11030930" @default.
• W4327728823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36979909" @default.
• W4327728823 hasPublicationYear "2023" @default.
• W4327728823 type Work @default.
• W4327728823 citedByCount "0" @default.
• W4327728823 crossrefType "journal-article" @default.
• W4327728823 hasAuthorship W4327728823A5027455398 @default.
• W4327728823 hasAuthorship W4327728823A5043391459 @default.
• W4327728823 hasAuthorship W4327728823A5054519106 @default.
• W4327728823 hasAuthorship W4327728823A5054849058 @default.
• W4327728823 hasAuthorship W4327728823A5063815140 @default.
• W4327728823 hasAuthorship W4327728823A5074136202 @default.
• W4327728823 hasAuthorship W4327728823A5077477606 @default.
• W4327728823 hasAuthorship W4327728823A5084736320 @default.
• W4327728823 hasAuthorship W4327728823A5087126798 @default.
• W4327728823 hasAuthorship W4327728823A5089705166 @default.
• W4327728823 hasBestOaLocation W43277288231 @default.
• W4327728823 hasConcept C137061746 @default.
• W4327728823 hasConcept C147483822 @default.
• W4327728823 hasConcept C159654299 @default.
• W4327728823 hasConcept C17991360 @default.
• W4327728823 hasConcept C202751555 @default.
• W4327728823 hasConcept C203014093 @default.
• W4327728823 hasConcept C2776090121 @default.
• W4327728823 hasConcept C2778062946 @default.
• W4327728823 hasConcept C2778128430 @default.
• W4327728823 hasConcept C2779727006 @default.

• next